tbuckley/cabot-search huggingface dataset:
Molecular mechanisms and targets of right ventricular fibrosis in pulmonary hypertension
Authors: F.T. Bekedam, M.J. Goumans, H.J. Bogaard, F.S. de Man, A. Llucià-Valldeperas
Journal: Pharmacology & Therapeutics (2023)

Right ventricular fibrosis is a stress response, predominantly mediated by cardiac fibroblasts. This cell population is sensitive to increased levels of pro-inflammatory cytokines, pro-fibrotic growth factors and mechanical stimulation. Activation of fibroblasts results in the induction of various molecular signaling pathways, most notably the mitogen-activated protein kinase cassettes, leading to increased synthesis and remodeling of the extracellular matrix. While fibrosis confers structural protection in response to damage induced by ischemia or (pressure and volume) overload, it simultaneously contributes to increased myocardial stiffness and right ventricular dysfunction. Here, we review state-of-the-art knowledge of the development of right ventricular fibrosis in response to pressure overload and provide an overview of all published preclinical and clinical studies in which right ventricular fibrosis was targeted to improve cardiac function.
The Grandmother's Letter
Authors: Maryella Desak Sirmon
Journal: Annals of Internal Medicine (2023)

Ad LibitumMarch 2023The Grandmother's LetterA villanelle on embryo adoptionMaryella Desak Sirmon, MDMaryella Desak Sirmon, MDUniversity of South Alabama, Mobile, AlabamaSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M22-3066 Audio Reading - “The Grandmother's Letter” Audio. Michael A. Lacombe, MD, Annals Associate Editor, reads “The Grandmother's Letter” by Maryella Desak Sirmon, MD Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Small piece of me, though you will never know,cold holds you fast. In cylinders you wait,whose love will warm you, freeing you to grow?Dearest, how much longer? How far to go?Safe today, I pray kindness is your fate,small piece of me though you will never know.Some not-yet mother dreams of you, althoughher hopes, your truth will one day incubate.Whose love will warm you, freeing you to grow?Do those who brought you life suffer sorrowbecause for them you seemed a heavy weight?Small piece of me though you will never know.futures with ... Author, Article, and Disclosure InformationAffiliations: University of South Alabama, Mobile, AlabamaCorresponding Author: Maryella Desak Sirmon, MD; e-mail, [email protected]com. PreviousarticleNextarticle Advertisement Audio Reading - “The Grandmother's Letter” Audio. Michael A. Lacombe, MD, Annals Associate Editor, reads “The Grandmother's Letter” by Maryella Desak Sirmon, MD Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ FiguresReferencesRelatedDetails Metrics Current IssueMarch 2023Volume 176, Issue 3Page: 423 ePublished: 21 March 2023 Issue Published: March 2023 Copyright & PermissionsCopyright © 2023 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Good Publication Practice (GPP) Guidelines for Company-Sponsored Biomedical Research: 2022 Update
Authors: Farah Asif
Journal: Annals of Internal Medicine (2023)

LettersMarch 2023Good Publication Practice (GPP) Guidelines for Company-Sponsored Biomedical Research: 2022 UpdateFarah Asif, MBBS, MScFarah Asif, MBBS, MScShaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, PakistanAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L22-0489 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR: DeTora and colleagues' revised GPP guidelines (1) are helpful, and their publication is appreciated. I thank the authors for paying attention to inclusivity and addressing the needs of marginalized and minority groups. The initiative of considering inclusivity in publication steering committees and working groups by including colleagues from different geographic regions and with different job roles and varied demographic characteristics (such as sex or gender, race, and national origin) is very insightful. However, it should be kept in mind at all times that members of marginalized groups and low- and middle-income countries as well as women might ...Reference1. DeTora LM, Toroser D, Sykes A, et al. Good Publication Practice (GPP) guidelines for company-sponsored biomedical research: 2022 update. Ann Intern Med. 2022;175:1298-304. [PMID: 36037471] doi:10.7326/M22-1460 LinkGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, PakistanDisclosures: Authors have reported no disclosures of interest. Forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L22-0489. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoGood Publication Practice (GPP) Guidelines for Company-Sponsored Biomedical Research: 2022 Update Lisa M. DeTora , Dikran Toroser , Angela Sykes , Christine Vanderlinden , Fiona J. Plunkett , Trevor Lane , Eline Hanekamp , Laura Dormer , Faith DiBiasi , Dan Bridges , Lise Baltzer , and Leslie Citrome Good Publication Practice (GPP) Guidelines for Company-Sponsored Biomedical Research: 2022 Update Lisa M. DeTora , Trevor Lane , Angela Sykes , Faith DiBiasi , Dikran Toroser , and Leslie Citrome Good Publication Practice (GPP) Guidelines for Company-Sponsored Biomedical Research: 2022 Update Robert Reinhard Metrics Current IssueMarch 2023Volume 176, Issue 3KeywordsClinical trialsDisclosureResearch ethicsResearch reporting guidelines ePublished: 21 March 2023 Issue Published: March 2023 Copyright & PermissionsCopyright © 2023 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Proteinuria and hematuria after remission induction are associated with outcome in ANCA-associated vasculitis
Authors: Nicolas Benichou, Pierre Charles, Benjamin Terrier, Rachel B. Jones, Thomas Hiemstra, Luc Mouthon, Ingeborg Bajema, Annelies Berden, Eric Thervet, Loïc Guillevin, David Jayne, Alexandre Karras
Journal: Kidney International (2023)
PARsylation-mediated ubiquitylation: lessons from rare hereditary disease Cherubism
Authors: Yoshinori Matsumoto, Robert Rottapel
Journal: Trends in Molecular Medicine (2023)

Modification of proteins by ADP-ribose (PARsylation) is catalyzed by the poly(ADP-ribose) polymerase (PARP) family of enzymes exemplified by PARP1, which controls chromatin organization and DNA repair. Additionally, PARsylation induces ubiquitylation and proteasomal degradation of its substrates because PARsylation creates a recognition site for E3-ubiquitin ligase. The steady-state levels of the adaptor protein SH3-domain binding protein 2 (3BP2) is negatively regulated by tankyrase (PARP5), which coordinates ubiquitylation of 3BP2 by the E3-ligase ring finger protein 146 (RNF146). 3BP2 missense mutations uncouple 3BP2 from tankyrase-mediated negative regulation and cause Cherubism, an autosomal dominant autoinflammatory disorder associated with craniofacial dysmorphia. In this review, we summarize the diverse biological processes, including bone dynamics, metabolism, and Toll-like receptor (TLR) signaling controlled by tankyrase-mediated PARsylation of 3BP2, and highlight the therapeutic potential of this pathway.
How to save a life: From neurobiological underpinnings to psychopharmacotherapies in the prevention of suicide
Authors: Xenia Gonda, Peter Dome, Gianluca Serafini, Maurizio Pompili
Journal: Pharmacology & Therapeutics (2023)

The impact of suicide on our societies, mental healthcare, and public health is beyond questionable. Every year approximately 700 000 lives are lost due to suicide around the world (WHO, 2021); more people die by suicide than by homicide and war. Although suicide is a key issue and reducing suicide mortality is a global imperative, suicide is a highly complex biopsychosocial phenomenon, and in spite of several suicidal models developed in recent years and a high number of suicide risk factors identified, we still have neither a sufficient understanding of underpinnings of suicide nor adequate management strategies to reduce its prevalence. The present paper first overviews the background of suicidal behavior including its epidemiology, age and gender correlations, and its association with neuropsychiatric disorders as well as its clinical assessment. Then we give an overview of the etiological background, including its biopsychosocial contexts, genetics and neurobiology. Based on the above, we then provide a critical overview of the currently available intervention options to manage and reduce risk of suicide, including psychotherapeutic modalities, traditional medication classes also providing an up-to-date overview on the antisuicidal effects of lithium, as well as novel molecules such as esketamine and emerging medications and further molecules in development. Finally we give a critical overview on our current knowledge on using neuromodulatory and biological therapies, such as ECT, rTMS, tDCS, and other options.
On the Labels We Carry
Authors: Michelle Izmaylov
Journal: Annals of Internal Medicine (2023)

On Being a DoctorMarch 2023On the Labels We CarryMichelle Izmaylov, MDMichelle Izmaylov, MDVanderbilt University Medical Center, Nashville, TennesseeSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M22-3665 Audio Reading - “On the Labels We Carry” Audio. Michael A. Lacombe, MD, Annals Associate Editor, reads “On the Labels We Carry” by Michelle Izmaylov, MD Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail I am led into a classroom in elementary school where students sit in rows and look at the board with markings we do not yet realize are words. This is English as a Second Language—ESL—class. I do not realize it then, but when I walk into that classroom, there is a label stamped on to me: the student in ESL class.The teacher wrinkles her nose when we do not answer her questions spoken in a language we do not yet know. Some of us learn quickly enough to understand when she stands at the front of the classroom and ... Author, Article, and Disclosure InformationAffiliations: Vanderbilt University Medical Center, Nashville, TennesseeCorresponding Author: Michelle Izmaylov, MD; e-mail, michelle.l.izmaylov.[email protected]org. PreviousarticleNextarticle Advertisement Audio Reading - “On the Labels We Carry” Audio. Michael A. Lacombe, MD, Annals Associate Editor, reads “On the Labels We Carry” by Michelle Izmaylov, MD Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ FiguresReferencesRelatedDetails Metrics Current IssueMarch 2023Volume 176, Issue 3Page: 421 ePublished: 21 March 2023 Issue Published: March 2023 Copyright & PermissionsCopyright © 2023 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Evaluating the impact of alcohol minimum unit pricing on deaths and hospitalisations in Scotland: a controlled interrupted time series study
Authors: Grant M A Wyper, Daniel F Mackay, Catriona Fraser, Jim Lewsey, Mark Robinson, Clare Beeston, Lucie Giles
Journal: The Lancet (2023)

Since May 1, 2018, every alcoholic drink sold in Scotland has had minimum unit pricing (MUP) of £0·50 per unit. Previous studies have indicated that the introduction of this policy reduced alcohol sales by 3%. We aimed to assess whether this has led to reductions in alcohol-attributable deaths and hospitalisations.Study outcomes, wholly attributable to alcohol consumption, were defined using routinely collected data on deaths and hospitalisations. Controlled interrupted time series regression was used to assess the legislation's impact in Scotland, and any effect modification across demographic and socioeconomic deprivation groups. The pre-intervention time series ran from Jan 1, 2012, to April 30, 2018, and for 32 months after the policy was implemented (until Dec 31, 2020). Data from England, a part of the UK where the intervention was not implemented, were used to form a control group.MUP in Scotland was associated with a significant 13·4% reduction (95% CI -18·4 to -8·3; p=0·0004) in deaths wholly attributable to alcohol consumption. Hospitalisations wholly attributable to alcohol consumption decreased by 4·1% (-8·3 to 0·3; p=0·064). Effects were driven by significant improvements in chronic outcomes, particularly alcoholic liver disease. Furthermore, MUP legislation was associated with a reduction in deaths and hospitalisations wholly attributable to alcohol consumption in the four most socioeconomically deprived deciles in Scotland.The implementation of MUP legislation was associated with significant reductions in deaths, and reductions in hospitalisations, wholly attributable to alcohol consumption. The greatest improvements were in the four most socioeconomically deprived deciles, indicating that the policy is positively tackling deprivation-based inequalities in alcohol-attributable health harm.Scottish Government.
Repurposing bacteria to fight disease
Authors: Priya Venkatesan
Journal: The Lancet Microbe (2023)

Antibiotic treatment of bacterial diseases is complicated by issues such as side effects from systemic drug administration, the widespread increase in antibiotic resistance, and the lack of new narrow-spectrum antibiotics being developed. Additionally, antibiotic therapy can inadvertently eliminate beneficial bacteria within the gut, detrimentally changing the gastrointestinal microbiome. This situation commonly occurs in individuals treated broad-spectrum antibiotics who then develop Clostridioides difficile infection.
Low versus standard calorie and protein feeding in ventilated adults with shock: a randomised, controlled, multicentre, open-label, parallel-group trial (NUTRIREA-3)
Authors: Jean Reignier, Gaetan Plantefeve, Jean-Paul Mira, Laurent Argaud, Pierre Asfar, Nadia Aissaoui, Julio Badie, Nicolae-Vlad Botoc, Laurent Brisard, Hoang-Nam Bui, Delphine Chatellier, Louis Chauvelot, Alain Combes, Christophe Cracco, Michael Darmon, Vincent Das, Matthieu Debarre, Agathe Delbove, Jérôme Devaquet, Louis-Marie Dumont, Olivier Gontier, Samuel Groyer, Laurent Guérin, Bertrand Guidet, Yannick Hourmant, Samir Jaber, Fabien Lambiotte, Christophe Leroy, Philippe Letocart, Benjamin Madeux, Julien Maizel, Olivier Martinet, Frédéric Martino, Virginie Maxime, Emmanuelle Mercier, Mai-Anh Nay, Saad Nseir, Johanna Oziel, Walter Picard, Gael Piton, Jean-Pierre Quenot, Florian Reizine, Anne Renault, Jack Richecoeur, Jean-Philippe Rigaud, Francis Schneider, Daniel Silva, Michel Sirodot, Bertrand Souweine, Fabienne Tamion, Nicolas Terzi, Didier Thévenin, Guillaume Thiery, Nathalie Thieulot-Rolin, Jean-Francois Timsit, Francois Tinturier, Patrice Tirot, Thierry Vanderlinden, Isabelle Vinatier, Christophe Vinsonneau, Sebastian Voicu, Jean-Baptiste Lascarrou, Amélie Le Gouge, Damien Contou, Olivier Pajot, Paul Jaubert, Nathalie Marin, Marie Simon, Martin Cour, Satar Mortaza, Vincent Souday, Marie Lemerle, Sylvain Malfroy, Fernando Berdaguer Ferrari, Bertrand Rozec, Didier Gruson, Charline Sazio, Suzanne Champion, Florence Boissier, Anne Veinstein, Loredana Baboi, Jean-Christophe Richard, Hodane Yonis, Loïc Le Guennec, Lucie Lefevre, Juliette Chommeloux, Guillaume Hékimian, Virginie Lemiale, Eric Mariotte, Sandrine Valade, Joanna Tirolien, Yannick Fedun, Charles Cerf, Guillaume Tachon, Jérôme Roustan, Sylvie Vimeux, Michel Bonnivard, Nadia Anguel, David Osman, Karim Asehnoune, Antoine Roquilly, Fouad Belafia, Matthieu Conseil, Moussa Cisse, Bouras Chaouki, Rémi Espenel, Christine Brasse, Sébastien Ena, Arnaud Delahaye, Jeremy Castanera, Thierry Dulac, Philippe Petua, Yoann Zerbib, Clément Brault, Djillali Annane, Rania Bounab, Nicholas Heming, Thierry Boulain, Sophie Jacquier, Grégoire Muller, Raphael Favory, Sébastien Préau, Julien Poissy, Alexandre Massri, Floriane Lissonde, Hadrien Winiszewski, Thibault Vieille, Marine Jacquier, Marie Labruyère, Pascal Andreu, Jean-Marc Tadié, Laetitia Bodenes, Danièle Combaux, David Luis, Antoine Marchalot, Jean-Etienne Herbrecht, Raphaël Clere-Jehl, David Schnell, Jérôme Aboad, David Bougon, Etienne Escudier, Elisabeth Coupez, Claire Dupuis, Zoe Demailly, Louis-Marie Galerneau, Jonathan Chelly, Franck Pourcine, Ly Van Vong, Sonia Abid, Etienne De Montmollin, Romain Sonneville, Christophe Guitton, Nicolas Chudeau, Mickaël Landais, Vincent Pages, Caroline Séjourné, Imen Rahmani, Ghada Sbouj, Bruno Megarbane, Nicolas Deye, Isabelle Malissin
Journal: The Lancet Respiratory Medicine (2023)
Intravenous ravulizumab in mechanically ventilated patients hospitalised with severe COVID-19: a phase 3, multicentre, open-label, randomised controlled trial
Authors: Djillali Annane, Sean J Pittock, Hrishikesh S Kulkarni, Brian W Pickering, Matt R Khoshnevis, Jason L Siegel, Charles A Powell, Pedro Castro, Tomoko Fujii, Derek Dunn, Keisha Smith, Sanjay Mitter, Shamsah Kazani, Austin Kulasekararaj
Journal: The Lancet Respiratory Medicine (2023)
Long-term safety of methylphenidate in children and adolescents with ADHD: 2-year outcomes of the Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects (ADDUCE) study
Authors: Kenneth K C Man, Alexander Häge, Tobias Banaschewski, Sarah K Inglis, Jan Buitelaar, Sara Carucci, Marina Danckaerts, Ralf W Dittmann, Bruno Falissard, Peter Garas, Chris Hollis, Kerstin Konrad, Hanna Kovshoff, Elizabeth Liddle, Suzanne McCarthy, Antje Neubert, Peter Nagy, Eric Rosenthal, Edmund J S Sonuga-Barke, Alessandro Zuddas, Ian C K Wong, David Coghill, Tessa Couper, Gabriele Masi, Antonella Gagliano, Marco Lamberti, Dino Maschietto, Antonella Costantino, Paola Morosini, Maria Elisa Fazzi, Klaus-Ulrich Oehler, Martina Pitzer, Jörg Fegert, Frank Häßler, Tobias Renner, Fabian Härtling, Marcel Romanos, Adam Alfred, Veit Roessner, Susanne Wallitza, Henrik Uebel-von Sandersleben
Journal: The Lancet Psychiatry (2023)
Alcestis
Authors: Rebekka DePew
Journal: Annals of Internal Medicine (2023)

Ad LibitumMarch 2023AlcestisRebekka DePew, MDRebekka DePew, MDWest Suburban Medical Center, Oak Park, IllinoisSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M22-1169 Audio Reading - “Alcestis” Audio. Michael A. Lacombe, MD, Annals Associate Editor, reads “Alcestis” by Rebekka DePew, MD Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Those who die and then return areoften silentwhich has never once been attributed tohaving seen godsometimes when I come backI do not speaksometimes when I come backI smell on my children's breaththe tinge of flesh left too long unfedsinew without nervewe are lightning set to smolderI know that nowbefore I left I was toldthat the sun and the moon were too heavy forthe same skyI was not told that death would lingerI was not told that the river Styx was pettyand bureaucratic I was not toldasphodel in its ... Author, Article, and Disclosure InformationAffiliations: West Suburban Medical Center, Oak Park, IllinoisEditor's Note: In its mood and tone, in its sparse choice of words perfectly chosen, in its use of enjambment to compel the reader along, this poem haunted me. Why the title, I wondered? How does a woman from Greek mythology serve this poem? As Alcestis did down through the ages of literature, from Chaucer to Milton, from Handel, Glueck, and Schweitzer, to Rilke, Wilder, and Martha Graham? I will challenge you to do your own research to unveil this masterpiece of poetry. Corresponding Author: Rebekka DePew, MD; e-mail, [email protected]com. PreviousarticleNextarticle Advertisement Audio Reading - “Alcestis” Audio. Michael A. Lacombe, MD, Annals Associate Editor, reads “Alcestis” by Rebekka DePew, MD Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ FiguresReferencesRelatedDetails Metrics Current IssueMarch 2023Volume 176, Issue 3Page: 422 ePublished: 21 March 2023 Issue Published: March 2023 Copyright & PermissionsCopyright © 2023 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Tumor microenvironment-responsive artesunate loaded Z-scheme heterostructures for synergistic photo-chemodynamic therapy of hypoxic tumor
Authors: Jie Lv, Xiaoyu Wang, Xue Zhang, Runpei Xu, Shuyang Hu, Shuangling Wang, Meng Li
Journal: Asian Journal of Pharmaceutical Sciences (2023)

Tumor microenvironment (TME) with the particular features of severe hypoxia, insufficient endogenous H2O2, and overexpression of glutathione (GSH) markedly reduced the antitumor efficacy of monotherapy. Herein, a TME-responsive multifunctional nanoplatform (Bi2S3@[email protected]/Art NRs) was presented for synergistic photothermal therapy (PTT), chemodynamic therapy (CDT), and photodynamic therapy (PDT) to achieve better therapeutic outcomes. The Z-scheme heterostructured bismuth [email protected] nanorods (Bi2S3@Bi NRs) guaranteed excellent photothermal performance of the nanoplatform. Moreover, its ability to produce O2 and reactive oxygen species (ROS) synchronously could relieve tumor hypoxia and improve PDT outcomes. The densely coated polydopamine/ammonium bicarbonate (PDA/ABC) and hyaluronic acid (HA) layers on the surface of the nanoplatform enhanced the cancer-targeting capacity and induced the acidic TME-triggered in situ "bomb-like" release of Art. The CDT treatment was achieved by activating the released Art through intracellular Fe2+ ions in an H2O2-independent manner. Furthermore, decreasing the glutathione peroxidase 4 (GPX4) levels by Art could also increase the PDT efficiency of Bi2S3@Bi NRs. Owing to the synergistic effect, this nanoplatform displayed improved antitumor efficacy with minimal toxicity both in vitro and in vivo. Our design sheds light on the application of phototherapy combined with the traditional Chinese medicine monomer-artesunate in treating the hypoxic tumor.